
Medigene AG
- Jurisdiction
Germany - LEI
391200I33JD2DKZGDX06 - ISIN
DE000A40ESG2 (MDG1.DE )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. Read full profile
Fundamentals
- Net revenue
€6.67M - Gross margin
78.4% - EBIT
-€16.19M - EBIT margin
-242.9% - Net income
-€16.65M - Net margin
-249.8%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions